Brandt, SD; Kavanagh, PV. Addressing the challenges in forensic drug chemistry. Drug Test. Anal., 1 Mar 2017, 9 (3), 342-346. 120 kB. https://doi.org/10.1002/dta.2169
EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2015. 879 kB.
McLaughlin, G; Baumann, MH; Kavanagh, PV; Morris, N; Power, JD; Dowling, G; Twamley, B; O’Brien, J; Hessman, G; Westphal, F; Walther, D; Brandt, SD. Synthesis, analytical characterization and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta-positional isomers. Drug Test. Anal., 1 Sep 2018, 10 (9), 1404-1416. 20.6 MB. https://doi.org/10.1002/dta.2396 #3-FPM
Mardal, M; Miserez, B; Bade, R; Portolés, T; Bischoff, M; Hernández, F; Meyer, MR. 3-Fluorophenmetrazine, a fluorinated analogue of phenmetrazine: Studies on in vivo metabolism in rat and human, in vitro metabolism in human CYP isoenzymes and microbial biotransformation in Pseudomonas Putida and wastewater using GC and LC coupled to (HR)-MS techniques. J. Pharm. Biomed. Anal., 1 Sep 2016, 128, 485–495. 651 kB. https://doi.org/10.1016/j.jpba.2016.06.011 #3-Fluorophenmetrazine
Chapman, SJ. Novel Psychoactive Spectra: NMR of (mostly) Novel Psychoactive Substances. BLOTTER, 25 Jun 2018, 3 (2). https://doi.org/10.16889/isomerdesign-6 #3-FPM NMR
Grumann, C; Huppertz, LM; Bisel, P; Angerer, V; Auwärter, V. Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). Drug Test. Anal., 19 Feb 2019, 11 (7), 1009-1017. 555 kB. https://doi.org/10.1002/dta.2577 #3-FPM LC,MS
Mayer, FP; Burchardt, NV; Decker, AM; Partilla, JS; Li, Y; McLaughlin, G; Kavanagh, PV; Sandtner, W; Blough, BE; Brandt, SD; Baumann, MH; Sitte, HH. Fluorinated phenmetrazine “legal highs” act as substrates for high-affinity monoamine transporters of the SLC6 family. Neuropharmacology, 15 May 2018, 134 (A), 149-157. 1.2 MB. https://doi.org/10.1016/j.neuropharm.2017.10.006 #3-FPM
Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 1 May 2019, 298, 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #3-FPM
Anon. Ordinance amending the Annex to the New Psychoactive Substances Act [Neue-psychoaktive-Stoffe-Gesetz] as well as Annexes to the Narcotics Act [Betäubungsmittelgesetz]. 14 Mar 2019. 704 kB. #3-Fluorophenmetrazine
Okamoto, K; Akimoto, S; Ando, T; Ikeda, Y; Kurashima, N. Differentiation of regioisomeric analogs of controlled substances using GC-IR. JCCL, 1 Oct 2016, (56), 49–70. 4.5 MB. #3-FPM Japanese, English abstract GC,MS,IR
Sasaki, R; Kato, M; Matsumoto, T; Udagawa, A; Matsuzaki, R. Analytical data of designer drugs of synthetic phenethylamines. JCCL, 1 Dec 2015, (55), 43–63. 637 kB. #10 Japanese, English abstract MS,NMR,IR,UV
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV. J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #F1 LC
WHO. WHO Expert Committee on Drug Dependence: Forty-third Report. World Health Organization, 1 Jan 2021. 1.9 MB. #3-FPM
McLaughlin, G; Morris, N; Kavanagh, PV; Dowling, G; Power, JD; Twamley, B; O’Brien, J; Talbot, B; Sitte, HH; Brandt, SD. Test purchase, synthesis and characterization of 3-fluorophenmetrazine (3-FPM) and differentiation from its ortho- and para-substituted isomers: Synthesis and characterization of fluorophenmetrazine positional isomers. Drug Test. Anal., 1 Mar 2017, 9 (3), 369-377. 1.3 MB. https://doi.org/10.1002/dta.1945 #3-FPM GC,MS,NMR,TLC,other